Waters Corporation (WAT)
Technical, fundamental, and sentiment analysis with recent related videos.
WAT rates Bullish overall. The fundamental read is neutral: the company passes 3 of 9 quality tests on the Piotroski F-Score; balance sheet is in the Safe zone (Altman Z = 13.95); revenue is growing about 2.2% per year; net income is declining about 3.1% per year. The technical picture is bullish: price is 27.2% above the 200-day moving average; 9.9% above the 50-day; the 50/200 relationship is in a Golden cross. Sentiment is bullish (composite 75/100), based on 8 news articles from recent coverage.
Revenue 3-year avg +2.2%. Net income 3-year avg -3.1%.
Price vs 20DMA +6.3%. RSI 69.52. Bollinger state: Above Upper Band.
Composite score 75/100 from the AI judge, based on 8 news items, 0 television segments, and 0 videos.
Latest Market Read
Waters shows a split picture. Fundamentals are Neutral: revenue has averaged 2.2 percent per year over three years while net income averaged -3.1 percent per year, so profits lag. Technicals are Bullish, price sits about 6.3 percent above the 20-day moving average (the average closing price over the last 20 trading days), the Relative Strength Index (RSI), a momentum reading, is 69.5 and the stock is trading above the upper Bollinger Bands (a volatility channel). Sentiment is Bullish at 75/100. The combination yields an Overall Bullish rating because strong technical momentum and positive sentiment outweigh neutral fundamentals, though below-average volume mutes conviction.
Recent news: Coverage is predominantly positive, highlighting new partnerships with Labcorp and Quest to expand access to the BD Onclarity HPV Assay across clinician and at‑home channels and a planned comprehensive FDA‑approved HPV test rollout beginning late 2026. Analysts also point to product momentum from LC‑MS launches (Xevo TQ Absolute XR IVD and Xevo MRT P10), BD integration progress, and a small institutional buy by Pinnacle, while a minority of commentary raises valuation concerns and notes the late‑2026 timing for diagnostics revenue. Overall the sources align toward constructive near‑term sentiment but flag valuation and timing risks.
Latest Videos
- No qualified videos yet.